EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - EyePoint is a leader in sustained-release drug delivery for retinal diseases [3] - The company's lead product, DURAVYU, is currently in Phase III trials for wet age-related macular degeneration [3] - Both Phase III trials for DURAVYU are fully enrolled, with top-line data expected midyear [3] Product Development - DURAVYU is also in Phase III trials for diabetic macular edema (DME), with the first patients expected to be dosed this quarter [3] - The proprietary delivery system, Durasert, has been utilized in four FDA-approved products, demonstrating a strong safety and efficacy record [3] Leadership and Experience - EyePoint has a veteran leadership team with over three decades of experience in clinical drug development and successful commercialization [3]